Table 1. Patient characteristics.

Characteristic	No. of patients	%
Age, (years)
<5	4	14
5–9	5	18
10–14	12	43
15–21	7	25
Sex
Male	14	50
Female	14	50
Diagnosis
Soft tissue sarcoma (MMT 98)	5	18
Rhabdomyosarcoma (MMT 98)	12	43
PNET	11	39
Additional chemotherapy
Etoposide	17	61
Cyclophosphamide	28	100
Thiotepa	11	39

PNET, primitive neuroectodermal tumour.

For patients treated on the MMT 98 study, cyclophosphamide (2 g m⁻² day⁻¹ × 3) was administered to patients on two courses of treatment, 6 and 2 weeks before receiving high-dose carboplatin, with etoposide (800 mg m⁻² day⁻¹ × 3) given 4 weeks before carboplatin. Patients treated on the PNET study received both cyclophosphamide (2 g m⁻² day⁻¹ × 2) and thiotepa (300 mg m⁻² day⁻¹) before high-dose carboplatin with time between chemotherapy treatments dependent on neutrophil and platelet count recovery.